Search results

Technologies 2

• NanoRx: Mechanically-Activated Drug Targeting
  The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...
• Microfluidic Hemostasis Monitor
  The body’s ability to stop bleeding, also known as hemostasis, is critical for survival. For patients with blood clotting disorders, medical conditions requiring the use of anticoagulation or antiplatelet drugs, or who require treatment with extracorporeal devices that circulate their blood outside of the body, it is essential that care providers can rapidly monitor their...

News 5

View all

• Press Release
  
  Platelet “Decoys” Outsmart Both Clots and Cancer
  February 13, 2019
• Translation News
  
  Predicting side effects before they happen
  May 1, 2018
• Press Release
  
  Pulmonary Thrombosis-on-a-Chip provides new avenue for drug development
  May 22, 2017

Multimedia 2

• 

  Video/Animation
  NanoRx: Clot-Busting Nanotherapeutic
  In this animation, learn how the Wyss Institute clot-busting nanotherapeutic is activated by fluid high shear force – which occurs where blood flows through vessels narrowed by obstruction – to specifically target clots and dissolve them away. By pairing this drug with an intra-arterial device that restores blood flow to complete obstructions, the drug-device combination...

• 

  Video/Animation
  Clot-busting nanotherapeutic
  Wyss Core Faculty member Donald E. Ingber describes the clot-busting nanotherapeutic. Credit: Wyss Institute at Harvard University